34 related articles for article (PubMed ID: 12407485)
1. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
2. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
[TBL] [Abstract][Full Text] [Related]
3. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Manosuthi W; Tantanathip P; Prasithisirikul W; Likanonsakul S; Sungkanuparph S
BMC Infect Dis; 2008 Oct; 8():136. PubMed ID: 18851761
[TBL] [Abstract][Full Text] [Related]
4. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
Dimala CA; Bechem NN; Aroke D; Kadia BM
BMC Res Notes; 2017 Nov; 10(1):623. PubMed ID: 29183354
[TBL] [Abstract][Full Text] [Related]
5. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.
Piscitelli SC; Kelly G; Walker RE; Kovacs J; Falloon J; Davey RT; Raje S; Masur H; Polis MA
Antimicrob Agents Chemother; 1999 Mar; 43(3):647-50. PubMed ID: 10049281
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y; Zhou H; Jiang Z; Wu D; Zhuang J; Li W; Jiang Q; Wang X; Huang J; Zhu H; Yang L; Du X; Li F; Xia R; Zhang F; Hu J; Li Y; Hu Y; Liu J; Jin C; Sun K; Zhou Z; Wu L; Yin H; Suo S; Yu W; Jin J
Am J Hematol; 2024 Apr; 99(4):774-779. PubMed ID: 38343062
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
Borjabad B; Inciarte A; Chivite I; Gonzalez-Cordon A; Mosquera M; Hurtado C; Rovira C; Gonzalez T; Sempere A; Torres B; Calvo J; De La Mora L; Martinez-Rebollar M; Laguno M; Foncillas A; Ambrosioni J; Blanch J; Rodriguez A; Solbes E; Llobet R; Berrocal L; Mallolas J; Miro JM; Alcami J; Blanco JL; Sanchez-Palomino S; De Lazzari E; Martinez E
J Antimicrob Chemother; 2024 Feb; 79(2):255-261. PubMed ID: 38039097
[TBL] [Abstract][Full Text] [Related]
8. Once vs twice-daily abacavir and lamivudine in African children.
Musiime V; Kasirye P; Naidoo-James B; Nahirya-Ntege P; Mhute T; Cook A; Mugarura L; Munjoma M; Thoofer NK; Ndashimye E; Nankya I; Spyer MJ; Thomason MJ; Snowden W; Gibb DM; Walker AS;
AIDS; 2016 Jul; 30(11):1761-70. PubMed ID: 27064996
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.
Schinazi RF; Hernandez-Santiago BI; Hurwitz SJ
Antiviral Res; 2006 Sep; 71(2-3):322-34. PubMed ID: 16716415
[TBL] [Abstract][Full Text] [Related]
10. Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.
Taburet AM; Paci-Bonaventure S; Peytavin G; Molina JM
Clin Pharmacokinet; 2003; 42(14):1179-91. PubMed ID: 14606928
[TBL] [Abstract][Full Text] [Related]
11. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
13. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
Rutherford GW; Sangani PR; Kennedy GE
Cochrane Database Syst Rev; 2003; (4):CD002037. PubMed ID: 14583945
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
Sension MG; Bellos NC; Johnson J; Sepulveda GE; DeJesus E; Santana JL; Ames MH; Goodwin SD
HIV Clin Trials; 2002; 3(5):361-70. PubMed ID: 12407485
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
